顺铂、培美曲塞、重组人血管内皮抑制素注射液联合治疗晚期肺腺癌的效果评价  

Effect evaluation of Cisplatin,Pemetrexed and Recombinant Human Endostatin Injection in the treatment of advanced lung adenocarcinoma

作　　者：丛云燕[1] 吕维泽[1] 林忠[1] 

机构地区：[1]中山大学附属第五医院肿瘤化疗科,广东珠海519000

出　　处：《中国当代医药》2017年第31期152-154,共3页China Modern Medicine

摘　　要：目的探讨顺铂、培美曲塞、重组人血管内皮抑制素注射液联合治疗晚期肺腺癌的效果。方法选取2013年6月~2016年6月我院收治的62例晚期肺腺癌患者作为研究对象,对其临床相关资料进行分析,将采用顺铂和培美曲塞进行治疗的30例患者作为对照组,将采用顺铂、培美曲塞及重组人血管内皮抑制素注射液进行治疗的32例患者作为观察组。比较两组患者的治疗效果和不良反应情况。结果观察组患者的疾病控制率(87.50%)高于对照组(63.33%),差异有统计学意义(P<0.05)。观察组患者的中位肿瘤进展时间(8个月)长于对照组(5.5个月),差异有统计学意义(P<0.05)。两组患者的生活质量提高有效率比较,差异无统计学意义(P>0.05)。两组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。结论将顺铂、培美曲塞及重组人血管内皮抑制素注射液联合应用于晚期肺腺癌患者的治疗中,可以将肿瘤的中位进展时间明显延长,且不会增加患者的不良反应,是一种有效的治疗方案,值得临床推广应用。Objective To investigate the effects of Cisplatin and Pemetrexed,Recombinant Human Endostatin Injection combined with chemotherapy in the treatment of advanced lung adenocarcinoma.Methods From June 2013 to June 2016,62 patients with advanced lung adenocareinoma treated in our hospital were selected as objects,and the clinical data was analyzed.30 patients who treated with Cisplatin and Pemetrexed was the control group,32 patients who treated with Cisplatin and Pemetrexed and Recombinant Human Endostatin Injection was the observation group.The treatment effects and adverse reactions were compared between the two groups.Results The disease control rate in the observation group （87.50%） was higher than that in the control group （63.33%）,and the difference was statistically significant （P〈 0.05）.The median tumor progression time in the observation group （8 months） was longer than that in the control group （5.5 months）,and the difference was statistically significant （P〈0.05）.The life quality increases efficiency were compared between the two groups,and the difference was not statistically significant （P〉0.05）.The adverse reaction rate were com- pared between the two groups,and the difference was not statistically significant （P〉0.05）.Conclusion The treatment of Cisplatin and Pemetrexed and Recombinant Human Endostatin Injection combined application in advanced lung adeno- carcinoma,the median time to progression of the tumor was significantly prolonged,and will not increase the adverse re- actions of patients.h is an effective treatment,worthy of clinical application.

关 键 词：顺铂 培美曲塞 重组人血管内皮抑制素注射液 晚期肺腺癌 生活质量 

分 类 号：R734.2[医药卫生—肿瘤]